Pharmaceuticals, Biotechnology and Life Sciences
Gilead Sciences will present findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment, at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Allergan has made another acquisition deal in expanding its medical aesthetics portfolio by buying Zeltiq Aesthetics for $2.475 billion.
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.
The global pharmaceutical grade silica gel market is projected to reach a market size of $71.05 million by 2025.
Acacia Pharma Group has made final pivotal Phase 3 study testing amisulpride injection Baremsis, formerly APD421, for patients with post-operative nausea & vomiting (PONV), after getting antiemetic prophylaxis, and now all phases met primary endpoints.
Orion Group has announced that Dr. Reijo Salonen, M.D., Ph.D., Senior Vice President for Research and Development of the Orion Group and member of the Executive Management Board of the Orion Group will step aside from his current positions as of 21 February 2017.
Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland (Orion), for its new Easyhaler combination product, a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
As German generics drugmaker Stada confirmed receiving offers to be bought out, it has simultaneously made a deal with a Sweden-based life science company Enzymatica, to sell its common cold mouth spray ColdZyme in Germany.
Ipsen has entered into a definitive agreement to acquire Sanofi’s five consumer healthcare products in certain European territories.
Verona Pharma said on Monday that, after the 50 for 1 share consolidation approved by shareholders on 8 February 2017, it now has 51,361,064 ordinary shares of £0.05 each in issue, each carrying one voting right.